Accordingly, the antagonists of ET-1 or inhibitors of ETA/ETB2 receptor are clinically important to prevent or treat cardiovascular illnesses including essential hypertension and PAH (Barton and Yanagisawa, 2019; Dhaun and Webb, 2019; Xiao et al., 2021). The gene discussed is EDN1; the disease is pulmonary arterial hypertension.